MGTX
NASDAQMeiraGTx Holdings plc
Price$9.09-0.06 (-0.71%)
01:30 PM07:45 PM
News · 26 weeks55-80%
2025-12-142026-06-07
Mix3290d
- SEC Filings14(44%)
- Insider9(28%)
- Other6(19%)
- Earnings2(6%)
- M&A1(3%)
Latest news
25 items- INSIDERCFO & COO Giroux Richard gifted 7,000 units of Ordinary Shares, decreasing direct ownership by 0.72% to 964,530 units (SEC Form 4)4 - MeiraGTx Holdings plc (0001735438) (Issuer)
- INSIDERPRESIDENT & CEO Forbes Alexandria sold $568,540 worth of Ordinary Shares (62,000 units at $9.17) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 1,387,695 units (SEC Form 4)4 - MeiraGTx Holdings plc (0001735438) (Issuer)
- SECSEC Form 144 filed by MeiraGTx Holdings plc144 - MeiraGTx Holdings plc (0001735438) (Subject)
- INSIDERSEC Form 4 filed by CHIEF DEVELOPMENT OFFICER Fleck Penny Renee4 - MeiraGTx Holdings plc (0001735438) (Issuer)
- INSIDERSEC Form 3 filed by new insider Fleck Penny Renee3 - MeiraGTx Holdings plc (0001735438) (Issuer)
- PRMeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Committee of the Company's Board of Directors approved equity awards to Penny Fleck in connection with her employment with the Company as Chief Development Officer. The equity awards were granted as an inducement material to the new employee entering employment with MeiraGTx in accordance with Nasdaq Listing Rule 5635(c)(4). Ms. Fleck received equity awards comprised of (i) non-qualified stock options to purchase 100,000 shares of the Company's ordinary shares with an exercise price equal to $9.9
- SECSEC Form 10-Q filed by MeiraGTx Holdings plc10-Q - MeiraGTx Holdings plc (0001735438) (Filer)
- SECMeiraGTx Holdings plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - MeiraGTx Holdings plc (0001735438) (Filer)
- PRMeiraGTx Reports First Quarter 2026 Financial and Operational ResultsReceived FDA Breakthrough Therapy Designation for AAV2-hAQP1Reported positive three-year data from the Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomiaEntered into an asset purchase agreement with Johnson & Johnson* (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP)Strengthened balance sheet with $100 million financing LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the first quarter ended March 31, 2
- SECAmendment: SEC Form SCHEDULE 13G/A filed by MeiraGTx Holdings plcSCHEDULE 13G/A - MeiraGTx Holdings plc (0001735438) (Subject)
- SECSEC Form DEFA14A filed by MeiraGTx Holdings plcDEFA14A - MeiraGTx Holdings plc (0001735438) (Filer)
- SECSEC Form DEF 14A filed by MeiraGTx Holdings plcDEF 14A - MeiraGTx Holdings plc (0001735438) (Filer)
- INSIDERAmendment: CHIEF MEDICAL OFFICER Zeldin Robert K covered exercise/tax liability with 7,814 units of Ordinary Shares, decreasing direct ownership by 5% to 146,204 units (SEC Form 4)4/A - MeiraGTx Holdings plc (0001735438) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by MeiraGTx Holdings plcSCHEDULE 13D/A - MeiraGTx Holdings plc (0001735438) (Subject)
- SECMeiraGTx Holdings plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - MeiraGTx Holdings plc (0001735438) (Filer)
- INSIDERDirector Perceptive Advisors Llc was granted 555,555 units of Ordinary Shares (SEC Form 4)4 - MeiraGTx Holdings plc (0001735438) (Issuer)
- INSIDERSEC Form 4 filed by Giroux Richard4 - MeiraGTx Holdings plc (0001735438) (Issuer)
- SECSEC Form 144 filed by MeiraGTx Holdings plc144 - MeiraGTx Holdings plc (0001735438) (Subject)
- SECSEC Form 424B5 filed by MeiraGTx Holdings plc424B5 - MeiraGTx Holdings plc (0001735438) (Filer)
- SECMeiraGTx Holdings plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - MeiraGTx Holdings plc (0001735438) (Filer)
- PRMeiraGTx Announces Pricing of $100 Million Offering of Ordinary SharesLONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the pricing of an underwritten offering of 11,111,111 of its ordinary shares at an offering price of $9.00 per share. Gross proceeds to MeiraGTx from the offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and offering expenses. All of the ordinary shares in the offering are being sold by MeiraGTx. The Company believes that the net proceeds from this offering, together with its existing cash and cash equivalents, will be sufficient to enable it to fund its
- SECMeiraGTx Holdings plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - MeiraGTx Holdings plc (0001735438) (Filer)
- PRMeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)Company entered into an asset purchase agreement with Johnson & Johnson (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP)MeiraGTx intends to immediately pursue global regulatory filings for approval of bota-vec LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that it has entered into an asset purchase agreement with Johnson & Johnson* (J&J) to acquire all interests in bota-vec for the treatment of XLRP. "We are extremely pleased to have reacquired bota-vec for the treatment of XLRP,"
- SECMeiraGTx Holdings plc filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - MeiraGTx Holdings plc (0001735438) (Filer)
- PRMeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced XerostomiaClinically meaningful improvements in xerostomia symptoms measured by PRO Xerostomia Questionnaire (XQ) maintained out to 3 years post treatment with AAV-hAQP1 for both bilateral and unilateral cohortsIncreases in Unstimulated Whole Saliva Flow Rate (UWSFR) maintained out to 3 yearsAAV-hAQP1 was safe and well tolerated at each dose testedAAV-hAQP1 Data presentation webcast to be held today, April 16, 2026, at 8:00 a.m. ET LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced positive three-year data from the completed Phase 1 AQUAx study of AAV-hAQP1 for the treatment
MGTX FAQ
7 questionsWhat does MeiraGTx Holdings plc do?
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced...Where does MGTX stock trade?
MeiraGTx Holdings plc (MGTX) is listed on NASDAQ.What sector and industry is MGTX in?
MeiraGTx Holdings plc operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did MeiraGTx Holdings plc go public?
MeiraGTx Holdings plc (MGTX) completed its IPO in 2018.What are analysts saying about MGTX?
MeiraGTx Holdings plc has had 3 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $2000.00 price target on 2025-11-24. Recent price targets range from $2000.00 to $3600.00.What companies are similar to MGTX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare MGTX side-by-side with any of them on Quantisnow.How can I track MGTX on Quantisnow?
Quantisnow aggregates MeiraGTx Holdings plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MGTX to receive live email and push alerts on every new disclosure.